P358: HYPER-CVAD WITH BLINATUMOMAB AND INOTUZUMAB OZOGAMICIN FOR PATIENTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-NEGATIVE B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA: A PHASE II STUDY [PDF]
Hemasphere, 2023 HemaSphere, Volume 7, Issue S3, August 2023.
Short N +17 more
europepmc +2 more sources
P637: TIME-LIMITED TREATMENT WITH ACALABRUTINIB PLUS OBINUTUZUMAB IN TREATMENT-NAÏVE CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS: EARLY RESULTS OF AN ONGOING PHASE 2 TRIAL [PDF]
Hemasphere, 2023 HemaSphere, Volume 7, Issue S3, August 2023.
Burger J +6 more
europepmc +2 more sources
Low Dose Pregabalin Improves Gastrointestinal Symptoms of Crohn's Disease. [PDF]
Case Rep Gastrointest MedInflammatory bowel diseases (IBD), including Crohn’s disease and ulcerative colitis, are lifelong conditions with no definite cure. Several studies demonstrated that patients with IBD more frequently experience symptoms of common mental disorders, such as anxiety and depression, because of bidirectional communication through the gut‐brain axis and the ...
D'Onofrio AM +4 more
europepmc +2 more sources
Current Status of Revisions to the Lugano Classification in Lymphoma. [PDF]
Hematol OncolABSTRACT In the decade since publication of the Lugano Classification (Cheson et al, J Clin Oncol 2014,32:3059–3068; Barrington et al, J Clin Oncol 2014, 32:3048–3058), major advances in lymphoma therapy and assessment, including metabolic tumor volume (MTV) and circulating tumor DNA (ctDNA) prompted a workshop at the International Conference on ...
Organizing Committee of the Lugano Classification Workshop.
europepmc +2 more sources
Law &Society Review, Volume 57, Issue 3, Page 340-363, September 2023., 2023 Abstract Law and globalization studies have documented how Global South lawyers compete over the adaptation of international norms. Yet, little is known about how this adaptation legitimates worldviews beyond the law. To advance this literature, this paper proposes a discourse‐centered field analysis of the legal globalization of anti‐corruption ideas ...
Eduardo Cornelius
wiley +1 more source
P1194: A PHASE IB TRIAL OF ITACITINIB COMBINED WITH ALEMTUZUMAB IN PATIENTS WITH T-CELL PROLYMPHOCYTIC LEUKEMIA (T-PLL) [PDF]
Hemasphere, 2022 HemaSphere, Volume 6, Issue S3, Page 1080-1081, June 2022.
Kadia T +14 more
europepmc +2 more sources
Hematological Oncology, Volume 41, Issue S1, Page 119-128, June 2023., 2023 Abstract The leukemic B cells from patients with chronic lymphocytic leukemia (CLL) require interactions with non‐malignant cells and matrix in the tissue microenvironment to survive and grow. These interactions are mediated through the B‐cell antigen receptor (BCR), C‐X‐C chemokine receptor type 4 (CXCR4), and a variety of integrins, including VLA‐4 ...
Shih‐Shih Chen, Nicholas Chiorazzi
wiley +1 more source
PB1883: TIME-LIMITED TREATMENT WITH ACALABRUTINIB PLUS OBINOTUZUMAB IN TREATMENT-NAÏVE CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS INDUCES DEEP REMISSIONS: EARLY RESULTS OF AN ONGOING PHASE 2 TRIAL. [PDF]
Hemasphere, 2022 HemaSphere, Volume 6, Issue S3, Page 1763-1764, June 2022.
Burger J +7 more
europepmc +2 more sources
P1590: OUTCOME OF HYPERBARIC OXYGEN THERAPY IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES –A TERTIARY CANCER CENTER EXPERIENCE [PDF]
Hemasphere, 2022 HemaSphere, Volume 6, Issue S3, Page 1471-1472, June 2022.
Kim K +7 more
europepmc +2 more sources